A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical
trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC)
versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). 687
subjects will be randomized to one of the following treatment arms in a 2:1 ratio,
fruquintinib plus BSC or placebo plus BSC.